Etanercept y neoplasias

García-Rabasco, A.; Sánchez-Carazo, J.L.; Esteve, A.

doi:10.1016/S0001-7310(10)70015-6

Article information

Resumen

La introducción de los fármacos bloqueadores del factor de necrosis tumoral (TNF) ha permitido un gran avance en el control y conocimiento de ciertas enfermedades inflamatorias, entre las que se incluye la psoriasis.

El TNF es una citocina que desempeña un papel clave en el control de infecciones y neoplasias.

El incremento del riesgo de desarrollar una neoplasia durante el empleo de este grupo de fármacos es uno de los efectos adversos más discutidos en la literatura.

Presentamos el caso clínico de una paciente con psoriasis de larga evolución que desarrolló un adenocarcinoma de mama tras iniciar el tratamiento con etanercept.

En este artículo realizamos una breve revisión acerca de la posible asociación existente entre el empleo de terapia anti-TNF y el riesgo de aparición de ciertas neoplasias, entre las que destacan las leucemias, los linfomas y determinados tumores sólidos.

Palabras clave:

Psoriasis

Neoplasia

TNF

Etanercept

Abstract

The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis.

TNF is a cytokine that plays a key role in the control of infections and neoplasms.

The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature.

We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept.

In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.

Keywords:

Psoriasis

Neoplasm

TNF

Etanercept

Full text is only aviable in PDF

Bibliografía

[1.]

B. Nair, G. Raval, P. Mehta.

TNF-a inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature.

Am J Hematol, 82 (2007), pp. 1022-1024

http://dx.doi.org/10.1002/ajh.20926 | Medline

[2.]

F. Balkwill.

Tumor necrosis factor or tumor promoting factor?.

Cytokine Growth Factor Rev, 13 (2002), pp. 135-141

Medline

[3.]

C. Comte, J.J. Guilhou, B. Guillot, O. Dereure.

Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis.

Dermatology, 217 (2008), pp. 284-285

http://dx.doi.org/10.1159/000150603 | Medline

[4.]

T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, V. Montori.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials.

JAMA, 295 (2006), pp. 2275-2285

http://dx.doi.org/10.1001/jama.295.19.2275 | Medline

[5.]

S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, M.M. Braun.

Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration.

Arthritis Rheum, 46 (2002), pp. 3151-3158

http://dx.doi.org/10.1002/art.10679 | Medline

[6.]

P. Geborek, A. Bladstrom, C. Turesson, A. Gulfe, I.F. Petersson, T. Saxne, et al.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas.

Ann Rheum Dis, 64 (2005), pp. 699-703

http://dx.doi.org/10.1136/ard.2004.030528 | Medline

[7.]

J. Askling, C.M. Fored, E. Baecklund, L. Brandt, C. Backlin, A. Ekbom, et al.

Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Ann Rheum Dis, 64 (2005), pp. 1414-1420

http://dx.doi.org/10.1136/ard.2004.033241 | Medline

[8.]

F. Wolfe, K. Michaud.

Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Arthritis Rheum, 50 (2004), pp. 1740-1751

http://dx.doi.org/10.1002/art.20311 | Medline

[9.]

J.M. Gelfand, J. Berlin, A. Van Voorhees, D.J. Margolis.

Lymphoma rates are low but increased in patients with psoriasis.

Arch Dermatol, 139 (2003), pp. 1425-1429

http://dx.doi.org/10.1001/archderm.139.11.1425 | Medline

[10.]

Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry. Ann Rheum Dis published online 14 Oct 2009; doi: 10.1136/ard. 2009.117762.

[11.]

E. Dommasch, J.M. Gelfand.

Is there truly a risk of lymphoma from biologic therapies?.

Dermatol Ther, 22 (2009), pp. 418-430

http://dx.doi.org/10.1111/j.1529-8019.2009.01258.x | Medline

[12.]

P. Lafaille, D. Bouffard, N. Provost.

Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept.

Arch Dermatol, 145 (2009), pp. 94-95

http://dx.doi.org/10.1001/archdermatol.2008.526 | Medline

[13.]

J. Friedberg, E. Jacobsen, D. Neuberg, J. Kutok, O. Munoz, V. Boussiotis, et al.

Targeting the follicular lymphoma microenviroment through blockade of TNF alfa with etanercept.

Leuk Lymphoma, 49 (2008), pp. 902-909

http://dx.doi.org/10.1080/10428190801950033 | Medline

[14.]

A.M. Tsimberidou, F.J. Giles, M. Duvic, R. Kurzrock.

Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.

J Am Acad Dermatol, 51 (2004), pp. 200-204

http://dx.doi.org/10.1016/j.jaad.2003.05.009 | Medline

[15.]

B.F. Chong, H.K. Wong.

Treatment of psoriasis with etanercept in a patient with primary B-cell lymphoma.

Clin Exp Dermatol, 34 (2009), pp. e11-e13

http://dx.doi.org/10.1111/j.1365-2230.2008.02973.x | Medline

[16.]

G. Bakland, H. Nossent.

Acute myelogenous leukaemia following etanercept therapy.

Rheumatology (Oxford), 42 (2003), pp. 900-901

[17.]

R.H.B. Meyboom, K. Star, J. Bate, I.R. Edwards.

TNF-a inhibitors and leukaemia: International Pharmacovigilance Reports.

Drug Safety, 31 (2008), pp. 445-447

Medline

[18.]

E.F. Chakravarty, K. Michaud, F. Wolfe.

Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

J Rheumatol, 32 (2005), pp. 2130-2135

Medline

[19.]

K.J. Smith, H.G. Skelton.

Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor a receptor IgG1-Fc fusion complex therapy.

J Am Acad Dermatol, 45 (2001), pp. 953-956

http://dx.doi.org/10.1067/mjd.2001.117725 | Medline

[20.]

L. Klareskog, L. Moreland, S. Cohen, et al.

Global safety and efficacy of up to five years of etanercept (Enbrel) therapy.

Arthritis Rheum, 44 (2001), pp. S77

[21.]

D. Burge.

Etanercept and squamous cell carcinoma.

J Am Acad Dermatol, 49 (2003), pp. 358-359

Medline

[22.]